Press Releases

Targeted immunotherapy offers promise for metastatic cervical cancer, according to Kunle Odunsi, MD, PhD, Cancer Center Deputy Director, Executive Director of the Center for Immunotherapy, and Chair of the Department of Gynecologic Oncology at Roswell Park Cancer Institute.

The latest research from the team that discovered the novel anticancer agent FL118 highlights distinctive characteristics of this small-molecule compound and provides insights into its ability to overcome the persistent problem of treatment resistance.

Cleveland BioLabs, Inc. and Roswell Park Cancer Institute today announced the award of a three-year, $1.2 million Breast Cancer Research Program Breakthrough Award to Roswell Park from the Department of Defense Congressionally Directed Medical Research Program for research into the immunotherapy of metastatic breast cancer with entolimod, a toll-like receptor 5 (TLR5) agonist.

Researchers at Roswell Park Cancer Institute (RPCI) have made new findings about the causes and impacts of RNA modification or “editing.” Innate immune cells — the body’s first line of defense — possess the ability to extensively change genetic information by means of RNA modification as a response to factors associated with inflammation

Roswell Park Cancer Institute (RPCI) researchers examined the characteristics of genetic variants in human toll-like receptor 5 (TLR5), and have found that these genetic variants may predict antitumor responses to entolimod, an immunotherapeutic agent with antitumor activity.

Researchers at Roswell Park Cancer Institute (RPCI) have identified common inherited gene alterations that appear to make some patients more at risk of neurotoxicity when treated for breast cancer.

Empire State Development (ESD) President, CEO & Commissioner Howard Zemsky and Roswell Park Comprehensive Cancer Center Chief Executive Officer and President Dr. Candace Johnson today announced that following the NYS Trade Mission to Cuba, Roswell Park Cancer Institute in Buffalo has signed an agreement with Cuba’s Center for Molecular Immunology (CIM) to develop a unique lung cancer vaccine with a clinical trial in the United States.

A first-of-its kind cancer vaccine, SurVaxM, has demonstrated safety and tolerability in patients with recurrent or progressive malignant brain tumors, according to results of a phase I study conducted by Roswell Park Cancer Institute (RPCI) researchers.